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SUMMARY
Introduction Recurrent depression is a psychiatric disorder of which etiology and pathogenesis might be 
related to immune response. Metabolic Syndrome (MetS) and its components are also strongly associated 
with elevated inflammatory indicators, as so as the body mass index (BMI) and total cholesterol levels.
Objective Objective of this study was to investigate if there was any difference in C-reactive protein 
(CRP) levels in patients with recurrent depressive disorder, treated with antidepressants, compared to a 
healthy control group of subjects and if there was an association between increased CRP levels and the 
presence of MetS in these two groups.
Methods Sixty subjects entered the study; of these 35 patients with the diagnosis of recurrent depressive 
disorder, while the healthy control group included 25 subjects. MetS was defined according to the NCEP 
ATP III criteria. The cut-off point for CRP was set at >5 mg /L.
Results There was no statistically significant difference in the prevalence of MetS and CRP values between 
the studied groups. Waist circumference and total cholesterol levels were significantly higher in the 
experimental group. Patients that fulfilled the criteria for MetS showed significantly higher values of 
central obesity and arterial hypertension in the experimental group as well. The elevated CRP levels were 
associated with increased frequency of MetS in depressed patients.
Conclusion Both CRP levels and metabolic risk profile screening, according to the international criteria, 
may be beneficial in order to obtain better assessment for depressive long term medicated patients.
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INTRODUCTION
Infectious and inflammatory processes could 
potentially play an important role in the etiol-
ogy and pathogenesis of depressive disorder [1, 
2]. C-reactive protein (CRP) is one of positive 
acute phase proteins that is synthesized in the 
liver and then excreted in the blood. Increased 
CRP levels are associated not only with acute 
but with chronic infections too [3].
Depression has been shown to be associated 
with activation of the inflammatory response. 
These changes include increased numbers of 
peripheral leucocytes, both monocytes and 
neutrophils [4]. This acute-phase response is 
an integral part of the inflammatory response 
and its purpose is to enable protein mobiliza-
tion, which serves to limit tissue damage and 
stimulate repair. CRP may be useful in predict-
ing cardiovascular events in patients with coro-
nary heart disease [5]. When traditional risk 
factors for coronary heart disease are adjusted, 
depressed individuals have a risk double that of 
the non-depressed population [6].
Newcomer [3] defined the Metabolic Syn-
drome (MetS) as a chronic mild inflammatory 
state. Furthermore, the presence of MetS is 
most important predictor of premature onset 
of cardiovascular disease (CVD). CRP, as the 
most specific biomarker of inflammation, is 
the independent risk factor for CVD as well. 
The Amsterdam Longitudinal Ageing Study re-
ported a relative risk of cardiac mortality of 1.6 
associated with depressive symptoms. However, 
this cardiac mortality relative risk increased to 
3.8 for those who were clinically depressed [7]. 
Laboratory and epidemiological data showed 
that CRP is associated mostly with insulin re-
sistance and obesity, but also with other sub-
components of MetS [8]. The link between 
depression and coronary heart disease may be 
mediated through inflammation. Atherosclero-
sis is preceded by inflammation with increased 
production of acute-phase proteins, including 
CRP and pro-inflammatory cytokines [9]. It 
seems reasonable to assume that depression 
increases the risk of coronary heart disease 
through its pro-inflammatory biology [10].
OBJECTIVE
Aim of this study was to investigate if there are 
any differences in parameters that constitute 
MetS, as well as in CRP levels, total cholesterol, 
and body mass index (BMI) in patients with re-  
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current depressive disorder treated with selective serotonin 
reuptake inhibitor (SSRI) medication, compared to healthy 
controls. Further, we wanted to examine variables – predic-
tors of MetS in both study groups. For the experimental 
group of patients the authors' interest was to determine 
if variables such as severity of depression measured by 
HAMD-21 scale [11], length of SSRI therapy, length of 
illness duration and smoking habits have an impact on 
CRP values >5 mg/L.
METHODS
Sixty subjects entered the study; 35 of them were patients 
with recurrent depression disorder on SSRI antidepressant 
medication in the Daily Hospital Ward of the Special Men-
tal Hospital "Gornja Toponica", Niš, and 25 healthy control 
subjects. The diagnosis of recurrent depressive disorder 
was made according to the diagnostic criteria of the Inter-
national Statistical Classification of Diseases and Related 
Health Problems, 10th Revision (ICD-10: F33) [12]. We 
used the Hamilton Depression Rating Scale (HAMD-21) 
for depression symptoms severity for the patients from the 
experimental group. A written informed consent was ob-
tained from all participants, under procedures approved 
by the Local Ethics Committee and in accordance with the 
Helsinki Declaration. Venipuncture was performed for all 
subjects between 8 and 9 a.m. after 12 hours overnight 
fast. Immediately after collecting blood samples, serum 
concentration of total cholesterol, high density lipoprotein 
cholesterol (HDL-C), low density lipoprotein cholesterol 
(LDL-C), triglycerides and serum glucose were determined 
using enzyme methods and commercial kits (Olympus Di-
agnostic, GmbH, Hamburg, Germany) on Olympus AU 
600 automated analyzer. CRP serum levels were deter-
mined using immunoturbidimetric method. The cut-off 
point for CRP elevation was set at 5 mg/L.
MetS was defined according to the Third Report of the 
Adult Treatment Panel – National Cholesterol Education 
Program (NCEP ATP III) criteria [13]; any 3 of 5 Cat-
egorical Cut-points: 1. Central adiposity (elevated waist 
circumference; 102 cm in men, 88 cm in women); 2. El-
evated triglycerides >1.7 mmol/L, or on drug treatment 
for elevated triglycerides; 3. Reduced HDL-C <1.0 mmol/L 
in men, <1.3 mmol/L in women, or on drug treatment 
for reduced HDL-C; 4. Elevated blood pressure >130 mm 
Hg systolic blood pressure or >85 mm Hg diastolic blood 
pressure or on antihypertensive drug treatment in patients 
with history of hypertension; 5. Elevated fasting glucose 
>5.6 mmol/L or on drug treatment for elevated glucose.
BMI was calculated by measuring patients' weight and 
height (kg/m2). Waist circumference (marker of central ad-
iposity) was measured in the midpoint of distance between 
the costal arc and iliac crest when the patient was standing 
up and in midexpirium. Blood pressure was measured with 
an aneroid sphygmomanometer in the office setting.
The subjects excluded from the study were those who 
showed symptoms of chronic or acute infection, allergies, 
past history of autoimmune diseases, or any other condi-
tion known to have affected the immune system for at least 
2 weeks before investigation. They were also free of using 
other concomitant drugs known to alter immune function.
Statistical analyses: baseline characteristics were com-
pared by the t-test for independent samples. For categorical 
variables the chi-square test was used. Univariate logistic 
regression analysis was used to access predictors of MetS 
and high values of CRP, respectively. The analyses were 
done using SPSS for Windows Version 18.0. Probability 
level of p<0.05 was considered to be statistically significant.
RESULTS
Experimental group of patients (diagnosis of recurrent 
depression disorder) included 35 subjects (18 male, 17 fe-
male) of average age 47.85±7.35 years. The average age of 
the healthy control subjects (n=25) was 45.08±4.93 years.
All subjects from the experimental group were on the 
permanent antidepressant SSRI medication from three 
months up to 24 months duration (mean value 8.57±5.46 
months). Severity of depressive symptoms measured by 
HAMD-21 scale showed that the majority of experimental 
group of patients were euthymic (n=19 or 54.29%), with 
HAMD score 8 or less, and the rest had mild depression 
(n=16 or 45.71%), with HAMD scores range 17-24. The av-
erage duration of illness (diagnosis of recurrent depressive 
disorder according to ICD 10 criteria) was 7.86±5.13 years.
Table 1 shows demographic, biochemical and inflam-
matory values in these two groups. Statistically significant 
differences (p<0.001) were found for variables waist cir-
cumference and total cholesterol levels.
Graph 1 shows the prevalence of patients with MetS 
in the experimental and control group, according to the 
presence of NCEP ATP III criteria and its individual com-
ponents. The prevalence of MetS was 48.6% in the ex-
perimental group, compared to 28% in the control group 
(χ2=2.53; p=0.112), with no statistically significant differ-
ence. However, two out of five constituting parameters of 
Table 1. Demographic features, biochemical and inflammatory vari-
ables of the study groups
Variable
Experimental 
group (n=35)
Control group 
(n=25) p 
value
X
–
SD X
–
SD
Gender (male/female) 18/17 13/12 0.586
Age (years) 47.85 7.35 45.08 4.93 0.197
BMI (kg/m2) 26.63 4.05 25.43 2.77 0.207
Waist (cm) 96.57 10.06 85.68 13.68 0.001*
Chol (mmol/L) 5.38 0.94 4.36 0.52 0.001*
Tg (mmol/L) 1.72 0.85 1.57 0.39 0.412
LDL-C (mmol/L) 3.01 0.94 2.95 0.37 0.750
HDL-C (mmol/L) 1.20 0.26 1.24 0.22 0.545
CRP (mg/L) 4.72 2.91 4.90 1.34 0.781
Gly (mmol/L) 4.71 1.94 4.36 0.43 0.374
* statistically significant p value
n – number of patients; X – mean value; SD – standard deviation; BMI – Body 
Mass Index; Waist – waist circumpherence; Chol – total cholesterol; Tg – trig-
lycerides; LDL-C – LDL cholesterol; HDL-C – HDL cholesterol; CRP – C-reactive 
protein; Gly – fasting glycose     
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MetS – obesity (i.e. central adiposity, high waist circumfer-
ence): χ2=4.17; p=0.04, and arterial hypertension: χ2=11.04; 
p<0.001 – showed statistical significance between the study 
groups, in favor of the experimental group of patients.
The authors wanted to investigate which were the most 
important correlates of MetS. For the experimental group 
of patients, results are presented on Table 2. Univariate 
logistic regression pointed to CRP as a statistically signifi-
cant variable (OR=4.668; 95%CI=1.540-14.269; p=0.007). 
Neither HAMD scores, length of antidepressants therapy, 
nor BMI values were found as significantly different.
In the control group the same method pointed at both 
CRP (OR=6.042; 95%CI=1.089- 33.518; p=0. 04) and BMI 
(OR=2.472; 95%CI=1.216-5.028; p=0.012) as significant 
correlates of MetS (Table 3).
Variables such as the length of SSRI medication (mon-
ths), length of depression illness (years), or severity of 
symptoms (patients with mild depression according to 
HAMD in our sample) were not significant indicators of 
high CRP values in the experimental group of patients. De-
rived data using the univariate logistic regression pointed 
at smoking habit only as a statistically significant correlate 
of high CRP values >5 mg/L (OR=4,156; 95%CI=1.399-
12.347; p=0,01) (Table 4).
DISCUSSION
The prevalence of MetS in our experimental group of 
patients with depression disorder was 48.6%, compared 
to 28% in the healthy control group of patients (p=0.11). 
Among the US adults 24% have MetS, and the prevalence 
increases with age (44% at age 60 years) [14]. The preva-
lence of MetS, according to the NCEP criteria, has been 
recently assessed in two independent investigations of 
patients with bipolar disorder. The first study evaluated 
171 patients and found the MetS prevalence of 30% [15]. 
The other study reported the MetS prevalence rate of 32% 
in a group of 125 bipolar patients [16]. Moreover, MetS 
was reported in 42.4% of 33 patients with schizoaffective 
disorder, bipolar type [17]. Similar to these results, a rela-
tively high percentage of MetS in our experimental group 
of patients should be considered in relation of their aver-
age age (47.85±7.35 years) as well as the average illness 
duration (7.86±5.13 years) and the presumption of poor 
physical activities.
Measured demographic (age, gender), physical (body 
mass index, waist circumference) biochemical (total cho-
lesterol, LDL-C, HDL-C, fasting glucose, triglycerides) 
and inflammatory (CRP) parameters showed a statistically 
significant differences (p<0.001) between the two study 
groups only for waist circumference and total cholesterol 
levels, favoring the experimental group of patients. Among 
the patients who fulfilled the criteria for MetS, statistical-
ly significant differences between the study groups were 
demonstrated for central obesity (high waist circumfer-
ence) and arterial hypertension (elevated blood pressure 
or on antihypertensive drug treatment). Two groups were 
compared with respect to lipid profiles of the cases in the 
study of Kirilmaz et al. [18]. Statistically significant el-
evations in levels of total cholesterol, triglycerides, blood 
pressure and LDL-C and a significantly decreased level of 
HDL-C were detected in the patients with MetS compared 
with the control group. According to body fat distribution, 
any increase in the mass of abdominal fat is an important 
determinant of mortality and morbidity and is in relation 
to many cardiovascular risk factors.
Table 2. Odds ratio (OR), significance (p) and confidence interval (CI) 
for Metabolic Syndrome correlates in the experimental group (n=35)
Factor OR 95%CI p
Smoking
[No] / / /
Yes 0.716 0.187–2.744 0.626
CRP 4.688 1.540–14.269 0.007*
BMI 1.211 0.974–1.505 0.085
SSRI length 0.984 0.863–1.122 0.812
HAMD score 0.988 0.815–1.197 0.900
* statistically significant p value
[ ] – referent group; SSRI length – length of permanent SSRI medication (months)
Table 3. Odds ratio (OR), significance (p) and confidence interval (CI) 
for Metabolic Syndrome correlates in the control group (n=25)
Factor OR 95%CI p
Smoking
[No] / / /
Yes 9.429 0.927–95.886 0.058
CRP 6.042 1.089–33.518 0.040*
BMI 2.472 1.216–5.028 0.012*
* statistically significant p value
[ ] – referent group
Table 4. Odds ratio (OR), significance (p) and confidence interval (CI) 
for the correlates of high CRP values (>5 mg/L) in experimental group 
(n=35)
Factor OR 95%CI p
Smoking
[No]
Yes 4.156 1.399–12.347 0.010*
Illness length (years) 0.964 0.842–1.104 0.597
SSRI length (months) 1.070 0.940–1.217 0.305
Mild depression 1.069 0.279–4.099 0.902
* statistically significant p value
[ ] – referent group; mild depression – patients with HAMD score 8–17 (n=16)
Graph 1. Prevalence (%) of metabolic syndrome and its individual 
components in the experimental and control group. Distribution of 
patients according to the NCEP ATP III criteria [13]
* statistically significant difference
MetS – metabolic syndrome; Obesity – central adiposity; High Gly – high fasting 
glucose; HTA – arterial hypertension; High TG – high triglyceri des; Low HDL – low 
high density lipoproteine  
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As the most important correlate for MetS presence in 
our experimental group of patients, univariate logistic 
regression indicated only CRP value at a statistically sig-
nificant level. Neither HAMD scores, length of antidepres-
sants therapy, nor BMI values were found to differ. In the 
control group, the same method pointed at both CRP and 
BMI as significant correlates of MetS. Numerous studies 
[19, 20] have now confirmed that CRP levels are elevated 
in patients with MetS. It has been claimed that there is 
a chronic and low-degree inflammatory status in MetS. 
CRP indicates the existence and degree of inflammation 
involving the vascular endothelium. Yet, it is still contro-
versial as to whether CRP is an inflammatory parameter 
or a risk factor. There is a linear relationship between the 
number of metabolic features and increasing levels of CRP. 
Furthermore, Festa et al. [21] in the Insulin Resistance 
and Atherosclerosis Study (IRAS) showed that CRP was 
positively correlated with BMI, waist circumference, trig-
lycerides, cholesterol, LDL-C, plasma glucose, and fasting 
insulin, and inversely correlated with HDL-C. The strong-
est associations are observed between CRP levels, central 
adiposity, and insulin resistance. The largest study to-date 
that examined the association between inflammation and 
MetS was the NHANES III study [22] which reported that 
CRP and fibrinogen levels and leukocyte counts were sig-
nificantly high in patients with MetS.
The cut-point for elevated values of CRP in our study 
was 5 mg/L. The authors also explored relationship among 
high CRP values and variables such as severity of depres-
sion measured by HAMD scale, length of SSRI therapy, 
length of illness duration and smoking habits. In our exper-
imental group, we had a subgroup of 16 patients qualified 
as „mild depression“ according to the HAMD score. This 
level of severity of depressive symptoms was not found as 
a correlate of elevated CRP values, neither did the length 
of antidepressive medication nor the length of the illness. 
However, some authors found an association of increased 
CRP levels with the severity of depressive symptoms [23] 
and normalization after antidepressant treatment [24], but 
findings are not consistent across studies. The reasons why 
CRP is selectively altered in manic, but not in depressed 
or euthymic patients are unknown [18]. The limitation 
of this study was that all patients who entered the study 
were taking SSRI medication for a certain time. Several 
studies have previously examined the association between 
CRP and depression, and the preponderance of evidence 
supports the conclusion that depression is associated with 
CRP but is confounded or mediated by other variables, 
particularly those that reflect fat mass [25, 26]. In a small 
case-control study in 1996, Sluzewska et al. [27] showed 
that CRP levels were significantly higher in patients with 
major depression compared with normal controls. No ad-
justment for possible confounders was performed.
Smoking habit was significant predictor for high CRP 
values in our study group of patients with recurrent de-
pressive disorder, while other examined variables (length 
of SSRI medication, length of depression illness, severity 
of depressive symptoms) were not. Similar observations 
reported Douglas et al. [28], on the large group of 696 
depressed patients, where total depression score did not 
independently correlate with CRP, and that any correlation 
between depression score and CRP could be explained by a 
relationship with other variables, such BMI, smoking habit, 
and blood pressure.
CONCLUSION
There was no statistically significant difference in the prev-
alence of MetS and CRP values between the experimental 
group of patients suffering from recurrent depression dis-
order treated with antidepressants and healthy control sub-
jects. Waist circumference and total cholesterol levels were 
significantly different in favor of the experimental group.
Elevated CRP levels were associated with increased risk 
for the development of MetS in depressed patients, while 
both CRP values and BMI were significant correlates of 
MetS for the control group. Smoking habit was a consider-
able predictor for high CRP values (5 mg/L) in the experi-
mental group of patients.
The severity of depression symptom (measured by 
HAMD score) and length of illness, indicated by the length 
of antidepressant drug treatment, did not show significant 
correlation with MetS and CRP.
Unfortunately, the scarcity of patients, the absence of 
subgroup of severely depressed patients (without previous 
medication) were a relevant limitation of our study.
Inflammation plays an important role in atheroscle-
rotic complications, which is activated in MetS. Increased 
number of MetS components is strongly associated with 
elevated inflammatory and metabolic markers. Measure-
ment of serum inflammatory parameters in psychiatric pa-
tients with MetS may be beneficial in prediction, detection 
and management of cardiovascular events.
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КРАТАК САДРЖАЈ
Увод Ре  ку  рент  ни де  пре  сив  ни по  ре  ме  ћај је пси  хи  ја  триј  ски 
ен  ти  тет чи  ја су ети  о  ло  ги  ја и па  то  ге  не  за у ве  зи с имун  ским 
од  го  во  ром. Ме  та  бо  лич  ки син  дром са сво  јим ком  по  нен  та  ма 
та  ко  ђе је у уској ве  зи с по  ви  ше  ним вред  но  сти  ма показатеља 
за  па  ље  ња, ин  дек  сом те  ле  сне ма  се и вред  но  сти  ма укуп  ног 
хо  ле  сте  ро  ла у се  ру  му.
Циљ ра  да Циљ сту  ди  је био је да ис  тра  жи има ли раз  ли  ке у 
ни  во  и  ма C-ре  ак  тив  ног про  те  и  на (CRP) из  ме  ђу ис  пи  та  ни  ка 
са ди  јаг  но  сти  ко  ва  ним ре  ку  рент  ним де  пре  сив  ним по  ре  ме-
ћа  јем ко  ји при  ма  ју ан  ти  де  пре  сив  ну те  ра  пи  ју (екс  пе  ри  мен-
тал  на гру  па) и здра  вих ис  пи  та  ни  ка (кон  трол  на гру  па), као и 
да ли по  сто  ји ве  за из  ме  ђу по  ве  ћа  них ни  воа CRP и за  сту  пље-
но  сти ме  та  бо  лич  ког син  дро  ма у ове две гру  пе ис  пи  та  ни  ка.
Ме  то  де ра  да Сту  ди  јом је об  у  хва  ће  но 60 ис  пи  та  ни  ка: 35 
са ди  јаг  но  зом ре  ку  рент  ног де  пре  сив  ног по  ре  ме  ћа  ја и 25 
здра  вих осо  ба. Ме  та  бо  лич  ки син  дром је де  фи  ни  сан пре  ма 
кри  те  ри  ју  ми  ма NCEP ATP III. По  ве  ћа  ним вред  но  сти  ма CRP 
сма  тра  ле су се оне ве  ће од 5 mg/l.
Ре  зул  та  ти Ни  је утвр  ђе  на ста  ти  стич  ки зна  чај  на раз  ли  ка у 
пре  ва  лен  ци  ји ме  та  бо  лич  ког син  дро  ма и ни  воа CRP из  ме  ђу 
ис  пи  ти  ва  них гру  па. Обим стру  ка и ни  во укуп  ног хо  ле  сте  ро-
ла би  ли су ста  ти  стич  ки зна  чај  но већи у екс  пе  ри  мен  тал  ној 
гру  пи. Код ис  пи  та  ни  ка ко  ји су за  до  во  љи  ли кри  те  ри  ју  ме за 
ме  та  бо  лич  ки син  дром уоче  на је ста  ти  стич  ки зна  чај  на раз-
ли  ка у ње  го  вим кон  сти  ту  тив  ним па  ра  ме  три  ма „цен  трал  на 
го  ја  зност“ и „ар  те  риј  ска хи  пер  тен  зи  ја“, та  ко  ђе у ко  рист екс-
пе  ри  мен  тал  не гру  пе. По  ве  ћа  ни ни  вои CRP у се  ру  му би  ли су 
удру  же  ни с по  ве  ћа  ним ри  зи  ком од по  сто  ја  ња ме  та  бо  лич  ког 
син  дро  ма у гру  пи де  пре  сив  них ис  пи  та  ни  ка.
За  кљу  чак Ме  ре  ње ни  воа CRP у се  ру  му и утвр  ђи  ва  ње по  сто-
ја  ња ме  та  бо  лич  ког син  дро  ма пре  ма ме  ђу  на  род  ним кри  те-
ри  ју  ми  ма мо  гу би  ти вр  ло ко  ри  сни у обез  бе  ђи  ва  њу ква  ли-
тет  ни  јег ле  че  ња де  пре  сив  них бо  ле  сни  ка на ду  же  вре  мен  ској 
ме  ди  ка  ци  ји ан  ти  де  пре  си  ви  ма.
Кључ  не ре  чи: C-ре  ак  тив  ни про  те  ин (CRP); ме  та  бо  лич  ки син-
дром; де  пре  си  ја; SSRI фар  ма  ко  те  ра  пи  ја
Метаболички синдром и C-реактивни протеин код болесника са депресивним 
поремећајем који примају антидепресивну терапију
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1Специјална болница за психијатријске болести „Горња Топоница“, Ниш, Србија;
2Специјална болница за психијатријске болести „Лаза Лазаревић“, Београд, Србија;
3Медицински факултет, Универзитет у Приштини, Косовска Митровица, Србија;
4Катедра за психијатрију, Медицински факултет, Универзитет у Крагујевцу, Крагујевац, Србија;
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